Navigation Links
Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs
Date:7/23/2008

Study results pending publication in July print edition of Clinical

Chemistry, available on Web

INDIANAPOLIS, July 23 /PRNewswire/ -- A Roche Diagnostics-sponsored pilot study evaluating the use of N-terminal pro-B-type natriuretic peptide (NT-proBNP) confirms the potential value of NT-proBNP for risk stratification in predicting the risk of cardiovascular adverse events (CV-AE) in patients treated with non-steroidal anti-inflammatory drugs of the COX inhibitor class.

The complete results of the study, currently available at http://www.clinchem.org , are scheduled for publication in the July print edition of Clinical Chemistry.

Non-steroidal anti-inflammatory drugs (NSAIDs) -- for example, acetylsalicylic acid and ibuprofen -- are the best known inhibitors of COX (cyclo-oxygenase), an enzyme involved in the inflammation pathway. This inhibition provides relief from the symptoms of the inflammation process; for example, fever and pain.

These drugs are routinely used to treat patients with osteoarthritis, rheumatoid arthritis and other pathologies associated with inflammation. However, studies with newer NSAIDs such as the selective COX-2 inhibitors (also called coxibs) have resulted in concern that there might be an increase in the risk of heart attack, thrombosis or stroke associated with long-term, high-dosage use of coxibs. Traditional NSAIDs (tNSAIDs) demonstrate comparable risks in observational studies.

Cardiovascular risk could be predicted

A pilot study(1) examined whether the risk of CV-AE could be predicted by measuring the NT-proBNP concentration in patients taking anti-inflammatory drugs. Baseline samples were measured by Elecsys proBNP (Roche Diagnostics) in 433 patients with osteoarthritis of the knees, with or without osteoarthritis of the hands, during an observational period of 200 days.

Cardiovascular adverse events -
'/>"/>

SOURCE Roche Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  Cepheid (Nasdaq: CPHD ) today announced ... Carba-R, with the addition of two newly emerging ... test also detects and differentiates among the five ... NDM, VIM, IMP-1 and OXA-48. "Carbapenem-resistant ... are a growing and expensive challenge for healthcare ...
(Date:7/29/2015)... PITTSBURGH , July 29, 2015  Mylan ... received regulatory clearance from the European Commission under the ... of Perrigo Company plc (NYSE: PRGO ; TASE).  ... Coury commented, "Today marks yet another important milestone ... and serves as further affirmation of the sound industrial ...
(Date:7/29/2015)... 29, 2015  Efforts to improve working capital efficiency ... firms in North America and ... an effective working capital management will ease the difficulties ... Big pharma companies expect to invest in optimizing working ... http://photos.prnewswire.com/prnh/20150724/241957LOGO Analysis from Frost ...
Breaking Medicine Technology:'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 2Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 3Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 5Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 6Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 7Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 8Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 9Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4
(Date:7/29/2015)... ... July 29, 2015 , ... CrossFit 269, offering ... July to Kalamazoo Strength & Conditioning. , The name change coincides with the ... of our training center over the past three years,” according to Jack Kelly, ...
(Date:7/29/2015)... ... 2015 , ... Today marks a significant achievement in bringing new monies into ... is led by a group of experienced investors, has tapped into an investor community ... to be a part of the fund. The Sofia Fund II is now ...
(Date:7/29/2015)... ... July 29, 2015 , ... July is National UV Awareness Month, and in honor ... shares tips on how to protect skin from the sun, as well as how to ... and is one of the most common skin conditions in America. Many people do not ...
(Date:7/29/2015)... Wis. (PRWEB) , ... July 29, 2015 , ... ... its first two patients in a Clinical Performance Study for the Invisiport at ... 4.4 and 6 French catheter options, offers a less invasive, patient-friendly alternative to ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... “forward thinker.” Since the late 1970s, Dr. Cottrell has been making predictions about ... The New Earth, documents many of these prognostications. He warns that extreme weather ...
Breaking Medicine News(10 mins):Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Sofia Fund Surpasses Investor Goals 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 3Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2
... strangulation game in 2005-2006 , , THURSDAY, Feb. 14 (HealthDay ... playing the "choking game" since 1995, a new government ... "pass out game," "scarf game," "space monkey" and other ... oneself or another with hands or some sort of ...
... Next Before Final Version is,Voted On, BETHESDA, Md., ... "national need" will include occupational,therapists if an agreement made ... AOTA staff worked fast and furiously to have the ... was able to have Representative Tom,Price of Georgia ask ...
... team of researchers was able to identify the location ... through analysis of genetic material (DNA) from members of ... from autosomal dominant juvenile cataract. The corresponding protein belongs ... molecules across cell mem-branes. Surprisingly, this genetic defect may ...
... , , THURSDAY, Feb. 14 (HealthDay News) -- A new ... found in the U.S.-banned insecticide DDT accelerates the growth ... in the open access journal Breast Cancer Research ... of a hormone that would otherwise help inhibit growth ...
... of the presidential nomination campaign, some candidates health care ... phrase socialized medicine has been used to attack health ... by the Harvard Opinion Research Program at the Harvard ... that Americans are split on whether a socialized medical ...
... available for all Minnesotans, MINNEAPOLIS, Feb. 14 ... such as a birthday or holiday as a "quit ... perfect day to,quit smoking for that special someone, and ... Services from ClearWay,Minnesota(SM)., Some romantic benefits of quitting, ...
Cached Medicine News:Health News:'Choking Game' Turned Deadly for 82 Youths 2Health News:'Choking Game' Turned Deadly for 82 Youths 3Health News:AOTA Gets Profession Addressed on House Floor in Federal Loan Repayment Bill 2Health News:New cataract gene discovered 2Health News:DDT Compound Speeds Breast Cancer Growth 2Health News:Poll finds Americans split by political party over views on socialized medicine 2Health News:Poll finds Americans split by political party over views on socialized medicine 3Health News:QUITPLAN(R) Services Can Help Make Valentine's Day Smoke-Free 2Health News:QUITPLAN(R) Services Can Help Make Valentine's Day Smoke-Free 3
... patented polymerase chain reaction (PCR) technology, the ... an essential component of Roches blood screening ... minute amounts of selected unique regions of ... of copies (that is, to detectable levels) ...
... BenchMark XT® the only fully automated ... you need to expand your test ... your slide turnaround time. All with ... how to use the BenchMark XT® ...
... Tonometer / Pachymeter is the first fully ... of IOP and CCT into one instrument., ... that have shown the importance of measuring ... pressure in the management of glaucoma patients, ...
... a process engineering and management consulting ... implementation of productivity improvement, quality control, ... industrial engineering, lean enterprise, and six ... cost effective solutions that drive and ...
Medicine Products: